Member Info for RuckRover

I know you all love a bit of AI.....

Ratcliffewriter’s style on LSE is pure sardonic theatre—equal parts forensic and farcical. He’s the kind of poster who dissects RNSs like a tax auditor with a hangover, then wraps the analysis in punchlines that wouldn’t be out of place in a Private Eye column.

Violin,

I suspect that had Diggle not bought 10 million shares, you'd still be holding.

You are just using his action as reassurance of your own decision.

Violin,

"we sit at 9.8 pence and suffered dilution along the way ."

Even as chief you can't count those as two separate moans. One is influenced by the other.

Easy to get them confused. Just remember:

Moditope trains T-cells to remember hidden threats.

Modi trains voters to forget inconvenient truths.

Yes, it certainly is punchy.

It would be quite a deviation from Scancell's usual style of clinically accurate rather than than sensationalist

". Your efforts today here have been transparent and frankly a bit painful."

I'm sorry you found them painful, I guess the truth hurts doesn't it?

C11,

“Who actually said conference attendance would result in an uptick in the share price? Not me.”

No you didn’t. So what ARE you hoping fo?

TF

"Ruck. Filtered again."

For what? Stating the truth that conference attendance rarely results in an uplift in SP - a small short term one at best.

Have you turned into a shrinking violet?

"Cheery as ever Ruck, never change. "

Well, from your comment I've probably been over optimistic with an uplift of 8.9% then.

" and it’s possible we may see a similar RNS soonish this year, relating to other conference attendance in the short term."

Well I can hardly contain my excitement- a possible 8.9 % uptick in the SP taking us to 11.4p.

Burble,

Yes, I found the same article. It's definitely the same person. She was diagnosed in 2014 so not the SCOPE trial. Could have been the original SCIB1 but also could be one of the CPIs. She thought it was NICE approved so would rule out SCIB1.

Researcher,

I don't think we can be sure either way. There is a possible it could be Scancell. They joined the NHS Cancer Vaccine Platform in April this year so while it is a short amount of time, it's not impossible.

Was this a recent broadcast and were there any other clues? Maybe worth posting a link for the scrutiny of the BB

Https://www.trinitydelta.org/research-notes/scopeing-out-iscib1-in-advanced-melanoma/

BB,

"From what they said is there any risk of more dilution in the near future? "

Not in the immediate future, no. Sath stated on two occasions they have 15 months worth of cash seeing us into H2 2026.

A question was asked whether this cash projection would be impacted by the new plans to accelerate towards P3 trials. He said no.

At some point in the next 12 month's additional funds will be needed from somewhere. There is always the risk that this will bring dilution. Other avenues of non-dilutive finance are being actively pursued.

Greenshaw,

Spot on. AI is going to have a massive impact on every aspect of human life. Unfortunately, there are many who can't see it yet so will be a start awakening when it finally dawns.

In fairness to empty though, there was nothing in the summary that couldn't be learned from watching all the videos.that would take you at least the total running time - a couple of hours versus 60 seconds to compose the questions and read the response.

Empty,

" It is utterly worthless to investors and, worse than that, has the capacity to seriously mislead."

So what was inaccurate and misleading in the 6.52 post I made?

TF,

"Of course, I don't 'prefer' "biased, abusive claptrap".

So why are you so anti AI which is unbiased, factual and has no agenda?

Surely you are not trying to say the BB is all these things at all times?

TF,

So you prefer the biased, abusive claptrap from some to this?

Phil L’Huillier, the CEO of Scancell, has made a series of compelling and forward-looking comments in recent interviews and presentations that reflect both optimism and strategic clarity about the company’s direction in cancer immunotherapy. Here's a breakdown of his key messages and my take on them:

Focus on Cancer Vaccines and NHS Collaboration

In his recent podcast with Citeline and interview with Drug Discovery World, L’Huillier emphasized:

The inclusion of Scancell’s melanoma vaccine on the NHS Cancer Vaccine Launch Pad, enabling broader and faster access for patients2

The importance of tackling tumour heterogeneity and enhancing immune response through Scancell’s platforms

My take: This marks a significant step in democratizing access to cutting-edge therapies. By leveraging national infrastructure like the NHS, Scancell is positioning itself not just as a biotech innovator but as a public health partner.

Clinical Progress and Data Highlights

In his Proactive Investors interview, L’Huillier shared:

80% disease control rate and 72% overall response rate in the SCOPE study for melanoma

Strong recruitment in both SCOPE and ModiFY trials

A new licensing deal with Genmab, validating Scancell’s antibody platform

A successful £11.3 million fundraising, securing runway through 2026

My take: These results are impressive, especially in late-stage melanoma where treatment options are limited. The dual mechanism of action in Scancell’s vaccines—boosting immune response and long-term control—could be a game-changer.

Strategic Vision and Leadership

Upon his appointment, L’Huillier stated:

“We are on the verge of a revolution in cancer therapy, driven by greater understanding of the human adaptive immune system.”5

He also praised the company’s platforms—ImmunoBody® and Moditope®—and expressed excitement about leading Scancell into late-stage clinical development.

My take: L’Huillier brings deep industry experience and a clear vision. His leadership seems to be catalyzing a shift from early-stage innovation to commercial readiness, which is crucial for biotech success.

Ee,

99% of postings on this board are not important. As a patent holder myself, I do have a passing interest in this area. My question was directed at Bermuda who has considerable knowledge in this area and always gives a polite response.

Thanks Bermuda, your thoughts are appreciated.